Arrowhead Research aims to price public offering of common-share units

Company sells its units through agent Dawson James Securities in deal

By Devika Patel

Knoxville, Tenn., Jan. 25 - Arrowhead Research Corp. will price a public sale of its units, according to a prospectus supplement filed Friday with the Securities and Exchange Commission.

The units will consist of one common share and a half-share warrant.

Dawson James Securities, Inc. is the agent.

Proceeds will be used for general corporate purposes, including working capital, capital expenditures, research and development expenditures and clinical trial expenditures.

Based in Pasadena, Calif., Arrowhead is a nanomedicine company developing therapeutics for the treatment of cancer and obesity, as well as the regeneration of wounded or diseased tissue.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.